Overview

Endpoint Validation Study (0524A-015)

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
To determine the most effective daily dose of MK0524A when compared with placebo after the 8-week treatment period for Niacin Induce Flushing (NIF).
Phase:
Phase 2
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Oxymetazoline